TY - JOUR
T1 - The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia
AU - Watts, Justin M.
AU - Bradley, Terrence
N1 - Publisher Copyright:
©2020 American Association for Cancer Research.
Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.
AB - Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.
UR - http://www.scopus.com/inward/record.url?scp=85087469561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087469561&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-0462
DO - 10.1158/1078-0432.CCR-20-0462
M3 - Comment/debate
C2 - 32284317
AN - SCOPUS:85087469561
VL - 26
SP - 3073
EP - 3076
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 13
ER -